ALT shares drop over 20% after updated pemvidutide week 48 data; see FDA's stance on non-invasive fibrosis tests. Click here ...
Altimmune said on Friday its experimental liver disease drug led to weight loss and improved markers for scarring and health of the organ based on non-invasive tests after 48 weeks of treatment in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback